<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-09T03:10:39Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/12244" metadataPrefix="oai_dc">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/12244</identifier><datestamp>2026-10-08T00:05:39Z</datestamp><setSpec>com_10259_6168</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_12236</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>Scaffold proteins and cytoskeletal dynamics as modulators of Ras-ERK pathway in cancer</dc:title>
<dc:creator>Fuente Vivas, Dalia de la</dc:creator>
<dc:creator>Casar, Berta</dc:creator>
<dc:creator>Crespo, Pedro</dc:creator>
<dc:subject>Citología</dc:subject>
<dc:subject>Bioquímica</dc:subject>
<dc:subject>Cytology</dc:subject>
<dc:subject>Biochemistry</dc:subject>
<dc:description>Póster presentado en: 41 Congreso de la SEBBM, Santander, 10-13 septiembre 2018</dc:description>
<dc:description>An overwhelming body of data unquestionably links the Ras-ERK&#xd;
pathway to the upbringing and progression of human malignancies.&#xd;
About 40% of human cancers harbor activating mutations in proteins&#xd;
involved in this signaling cascade, in particular Ras and Braf. In addition&#xd;
to the main proteins of this signaling pathway, there are several&#xd;
regulatory proteins known as scaffold proteins, that modulate the&#xd;
intensity, amplitude and duration of ERK signals. Interestingly, it can&#xd;
propose the scaffold proteins as antitumoral targets. Considering the&#xd;
hypothesis that scaffold proteins interact and regulate the signal&#xd;
transduction through the Ras-ERK pathway in a coordinated manner&#xd;
we try to find out how these interactions are regulated. Ras proteins&#xd;
are distributed in different types of plasma membrane: microdomains&#xd;
and endomembranes. We have previously demonstrated that&#xd;
compartmentalization dictates Ras utilization of effectors, the intensity&#xd;
of its signals and the biological response of the cells. Cell migration is&#xd;
critical for many physiological processes and is often misregulated in&#xd;
developmental disorders and pathological conditions including cancer.&#xd;
MAPK signaling are known regulators of cytoskeletal dynamics during&#xd;
cellular processes such as cell adhesion and migration. Our hypothesis&#xd;
is that localized ERK signaling mediated through recently identified&#xd;
scaffold proteins and its interactions with the cytoskeleton may&#xd;
regulate specific cellular responses. Here we propose that associations&#xd;
among different scaffold proteins and cytoskeleton will add one further&#xd;
degree of regulation for an already tightly regulated cascade and could&#xd;
provide a novel means for manipulating ERK signals, even with&#xd;
therapeutic purposes.</dc:description>
<dc:date>2026-10-07T10:59:47Z</dc:date>
<dc:date>2026-10-07T10:59:47Z</dc:date>
<dc:date>2018</dc:date>
<dc:type>info:eu-repo/semantics/conferenceObject</dc:type>
<dc:type>info:eu-repo/semantics/acceptedVersion</dc:type>
<dc:identifier>https://hdl.handle.net/10259/12244</dc:identifier>
<dc:language>eng</dc:language>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:format>application/pdf</dc:format>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>